The next-generation ultrasound system is a device that helps in integrating the number of imaging diagnoses related to a wide variety of clinical segments. This device is beneficial for making the diagnostic work more effectively using different technological aspects. Moreover, it is better in terms of quality, mobility, and affordability than the standard ultrasound system.
According to the MarkNtel Advisors' research report, "Global Next-Generation Ultrasound System Market Analysis, 2021," the market is likely to grow at a CAGR of around 5% during 2021-26 due to the surging demand for high-quality ultrasound systems in the healthcare sector and rapid adoption of technologically advanced devices like 3D, 4D, and future 5D ultrasound systems.
Further, the mounting prevalence of target diseases and snowballing government investments to support the R&D activities for developing next-generation ultrasound devices are primary factors fueling the market growth.
|Study Period||Historical Data: 2016-19|
|Base Year: 2020|
|Forecast Period: 2021-26|
|Regions Covered||North America: USA, Canada, Mexico|
|Europe: Germany, UK, France, Spain, Russia|
|Asia-Pacific: China, India, Japan, South Korea|
|South America: Brazil|
|Middle East & Africa: UAE, Saudi Arabia, South Africa|
|Key Companies Profiled||BK Medical ApS (Analogic Corporation), Butterfly Network Inc., Canon Inc., Clarius Mobile Health, Esaote SpA, Fujifilm Holdings Corporation, General Electric Company, Healcerion Co. Ltd., Hitachi Ltd., Hologic, Inc., Koninklijke Philips N.V., Samsung Electronics Co. Ltd., Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Shimadzu Corporation, Siemens Healthineers AG, Others|
|Unit Denominations||USD Million/Billion|
Impact of COVID-19
The sudden outbreak of the COVID-19 pandemic has adversely affected the Global Next-Generation Ultrasound System Market due to the lockdown imposition, movement restrictions, and stringent regulations and guidelines regarding the opening of manufacturing units, private clinics, and other laboratories. Moreover, supply chain disruptions, the declining number of skilled staff, and recruitment challenges for clinical trials further restrained the market growth.